Dexamethasone for Severe COVID Pneumonia: What Does the Data Show?
CEimpact Podcast
English - July 24, 2020 11:00 - 27 minutes - 18.6 MBCourses Education Science ceimpact podcast precept2practice level up gamechangers pharmacy cme cpe pharmacology ceimpact geoff wall Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: COVID Infections and the Latinx Patient: Perspectives from the Front Lines | GameChangers
Next Episode: Rational Use of Skeletal Muscle Relaxants | GameChangers
Overinflamation or cytokine storm is said to be the driver of acute respiratory disorder disease (ARDS) in COVID patients. A recent study conducted in the United Kingdom suggests that the steroid dexamethasone may be a weapon for prevention. In this episode, we discuss the study that caused the National Health Service in the U.K. and the CDC to change their recommendations for steroids and severe COVID.Additional Resources/ReferencesRamdomised Evaluation of COVID-19 Therapy: https://www.recoverytrial.net/ This episode is accredited for CPE. For CE details and to claim credit, click here: https://bit.ly/3h8OfTR See omnystudio.com/listener for privacy information.